Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02499120 | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | completed | Phase 2 | 125 | PfizerINDUSTRY | 15 | Sep 8, 2023 | clinicaltrials |
| NCT03624231 | Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC(DURTRE-RAD) | completed | Phase 2 | 18 | Ulrich KeilholzOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04929080 | The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC | completed | Phase 1 / Phase 2 | 149 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02207439 | Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03735680 | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer | completed | Phase 2 | 30 | OncoNano Medicine, Inc.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02949700 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 26 | Baylor College of MedicineOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00834093 | A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT01711541 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04291300 | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients(LUPSA) | completed | Phase 2 | 12 | Radboud University Medical CenterOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02707588 | Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC(PembroRad) | completed | Phase 2 | 133 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03999684 | A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Wei JiangOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03620123 | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck(OPTIM) | completed | Phase 2 | 54 | AIO-Studien-gGmbHOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT03405142 | Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | completed | Phase 2 | 3 | Eben RosenthalOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT01088802 | Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT03087019 | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | completed | Phase 2 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT01458392 | Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 46 | Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAINDUSTRY | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02002182 | ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer | completed | Phase 2 | 15 | Andrew SikoraOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT02268695 | Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC(TPExtreme) | completed | Phase 2 | 541 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 3 | Aug 23, 2022 | clinicaltrials |
| NCT01864772 | Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC(ELANFIT) | completed | Phase 2 | 85 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
| NCT01730638 | ImmunoTEP for Patients With Medullary Thyroid Carcinoma.(iTEP-CMT) | completed | Phase 1 / Phase 2 | 25 | Nantes University HospitalOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT01236547 | Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2022 | clinicaltrials |
| NCT03057613 | The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck | completed | Phase 2 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 30, 2022 | clinicaltrials |
| NCT02255097 | Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) | completed | Phase 2 | 172 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 28, 2022 | clinicaltrials |
| NCT01884259 | Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN(HNO-2) | completed | Phase 2 | 100 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT04834206 | Nedaplatin in Treatment for Nasopharyngeal Carcinoma | completed | Phase 2 | 32 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04508816 | Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | completed | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03292250 | Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] | completed | Phase 2 | 180 | Seoul National University HospitalOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03330249 | Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion(CisFRad) | completed | Phase 2 | 124 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT02684253 | Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) | completed | Phase 2 | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02873819 | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | completed | Phase 2 | 80 | Gliknik Inc.INDUSTRY | 7 | Mar 8, 2022 | clinicaltrials |
| NCT02562599 | Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin | completed | Phase 2 | 60 | Hubei Cancer HospitalOTHER | 1 | Feb 22, 2022 | clinicaltrials |
| NCT01104922 | Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 48 | David A. Clump, MD, PhDOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02237924 | Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma | completed | Phase 2 | 120 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02605967 | Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 122 | Novartis PharmaceuticalsINDUSTRY | 7 | Feb 10, 2022 | clinicaltrials |
| NCT02688608 | Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | completed | Phase 2 | 6 | Saad A KhanOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT03132038 | Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck(NISCAHN) | completed | Phase 2 | 98 | UNICANCEROTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT01332266 | E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 95 | Eisai Inc.INDUSTRY | 4 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | completed | Phase 2 | 5 | Seagen Inc.INDUSTRY | 2 | Nov 4, 2021 | clinicaltrials |
| NCT00592501 | Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT03096808 | Adaptive Radiotherapy for Head and Neck Cancer | completed | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT05020067 | Impact on Xerostomia for Nasopharyngeal Carcinoma Patients Treated With or Without Superficial Parotid Lobe-sparing Intensity-modulated Radiotherapy | completed | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03639168 | Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC) | completed | Phase 2 | 22 | Fudan UniversityOTHER | 1 | Aug 19, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 8, 2023source: clinicaltrials